EMA Creates Pediatric Drug Pilot Project
The agency launches initiative to stimulate pediatric drug development.
The European Medicines Agency (EMA) has announced the launch of a one-year pilot project that offers free interactive meetings with drug developers to discuss the potential for a drug’s use in pediatric patients before submission of a pediatric investigation plan (PIP). Pharmaceutical companies in the European Union that develop new drugs must also develop the drug to treat pediatric patients, and EMA’s Paediatric Committee (PDCO) must approve these PIPs.
During PIP assessments, EMA has found issues with the integration of adult and pediatric drug-development programs submitted by pharmaceutical companies causing potential delays in getting those drugs to children who need them. EMA hopes this pilot project will help developers optimize their drug-development programs and, therefore, speed up pediatric access to the medicine.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
